Q-omics provides the consensus-scored COQ8B profile across patient tissues and cancer cell-line models. COQ8B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, COQ8B is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, COQ8B RNA expression shows 19,275 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, KIRC, and ACC as cancer lineages where COQ8B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COQ8B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COQ8B survival associations across molecular data types. COQ8B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COQ8B RNA expression–survival associations across cancer types. High COQ8B expression shows unfavorable associations in LGG, UVM, ACC and LUAD, but favorable associations in SCLC and UCS. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for COQ8B RNA expression.
This table summarizes COQ8B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for COQ8B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COQ8B shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, LIHC, HNSC and BRCA. The KIRC box plot shows higher COQ8B RNA expression in tumor versus normal tissue (log2 FC = +0.864, t-test p < 0.001).
This table shows molecular features associated with COQ8B in patient tissues and cancer cell lines. In patient samples, COQ8B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, COQ8B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
